TRACT Therapeutics, Inc.

TRACT Therapeutics, Inc.

TRACT Therapeutics, Inc. has developed a novel approach for restoring immune balance in patients receiving a solid organ transplant or in patients suffering from an autoimmune disease. This therapeutic approach may potentially reduce the chance of organ rejection following a transplant or transfer a patient suffering from an autoimmune disease into a state of remission.

The proprietary technology is based on a platform which can be utilized to treat solid organ transplant patients, as well as a number of autoimmune disorders such as Crohn’s Disease. For organ transplant, it shows great promise in preventing rejection of a donated organ, thereby, reducing the need for a second transplant. Over the next few years, TRACT’s TregCel™ personalized therapy could transform the medical approach in transplant medicine by dramatically reducing or eliminating the lifelong use of toxic anti-rejection drugs.

Headquartered in the United States, TRACT Therapeutics, Inc. presents an innovative solution to critical medical challenges, with potential for significant impact in the field of organ transplant and autoimmune disease treatment. This pioneering technology has the potential to attract substantial interest from investors and revolutionize the current treatment paradigms.